Axsome settles SUNOSI patent litigation, allows generics starting 2040

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Axsome settles SUNOSI patent litigation, allows generics starting 2040

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

June 3, 2026 7:00 AM EDT

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsomes product SUNOSI (solriamfetol). The litigations resulted from submission of Abbreviated New Drug Applications to the U.S. Food and Drug Administration by companies seeking approval to market a generic version of SUNOSI in the United States.

Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement... More